Johns Hopkins University, Cedars-Sinai and Massachusetts General Hospital have raised $20 million to fuel a research initiative to understand the cause of amyotrophic lateral sclerosis.
Immuno-oncology player Adaptimmune has dipped into the ranks of its Big Pharma partner GlaxoSmithKline to find a leader for its biometrics team. The move sees Trupti Trivedi join Adaptimmune as VP, head of biometrics.
HudsonAlpha has rejigged its operation to cope with the torrent of genomes it unleashed when it installed an Illumina HiSeq X Ten. The new model is underpinned by Dragen, the processor Edico Genome has designed specifically to deal with the demands of sequencing data analysis.
GlaxoSmithKline has hitched its automation plans to Siemens. The deal makes Siemens the preferred automation supplier for production and R&D sites at GSK, positioning the conglomerate to shape how its partner incorporates advances in data integration into its operations.
AstraZeneca is pumping £11.5 million ($17.7 million) into a push to develop bioinformatics infrastructure to match its oncology ambitions. The money will finance a 5-year collaboration with the University of Manchester, during which AstraZeneca hopes to establish a bioinformatics system to match cancer patients to targeted therapies.
CD Genomics has started offering whole-genome sequencing services on its recently installed HiSeq X Ten system.
Thermo Fisher has stepped up its attempts to capture the targeted sequencing market with the introduction of the Ion S5 system. The next-generation sequencing system is pitched squarely at clinical trials and other fields in which a quick, affordable snapshot of a panel of genes is needed.
Labfolder has pulled in more than $1 million to finance development of its electronic lab notebook (ELN) system. The startup will use the cash to advance its vision of creating a system to connect researchers and the networks of equipment, software and data that support their work.
The U.S. National Institutes of Health has allocated $48.6 million to fuel the integration of genomic information into electronic health records (EHRs). The NIH is making the cash available in grants to more than 10 research teams, each of which is tasked with investigating a different aspect of the process.
Google is keeping up the pace of its push into diabetes. Having got the ball rolling by allying with Novartis in 2014, Google has now added Sanofi to its burgeoning list of diabetes collaborators.
The FDA has come good on its promise to make its stash of medical device data available publicly.
UCL has made Elsevier's PharmaPendium available to its researchers. The United Kingdom academic institution has subscribed to the resource to support its staffers' research into drug repurposing and the personalization of treatments.
The United Kingdom has opened up another front of its 100,000 Genomes Project. Having started off sequencing the genomes of people with rare diseases, the team behind the initiative are now ready to take aim at their other big target: cancer.
Over the past two years the reputation of the IT department at the FDA has changed rapidly. Once best known for burning through CIOs and receiving slapdowns from the congressional watchdog, the FDA is now garnering plaudits for its embrace of agile and open development. This new way of thinking is central to--and to an extent responsible for--the recently unveiled precisionFDA initiative.
The movement to shift informed consent in clinical trials from paper forms to electronic devices has notched up another victory. Mytrus and an unnamed top-10 pharma company made the advance by becoming the first organizations to win clearance to use e-consent in a trial in the United Kingdom.
J. Craig Venter's Human Longevity Inc. (HLI) has appointed a chief operating officer to manage its burgeoning genome sequencing operation. Mark Winham has taken up the position, jumping ship from drug-testing lab Millennium Health, where he also served as COO.
Biogen is working with Columbia University Medical Center to build a database of genes and clinical traits from 1,500 people with amyotrophic lateral sclerosis (ALS). The project, which is partly funded by cash raised in the Ice Bucket Challenge, is intended to help Biogen understand how genes contribute to different forms of ALS.
Google has just swept aside any lingering questions about how seriously it is taking its life sciences operation. Now, instead of operating as part of the experimental Google X, life sciences is to sit alongside the legacy internet search unit as one of a clutch of businesses operating under the Alphabet umbrella.
Boehringer Ingelheim has upgraded to the latest version of InnovoCommerce's innovoPOINT.